About This Trial
Monoclonal antibody targeting IL-33, a key upstream cytokine in allergic inflammation.
Primary Endpoints
- Severe exacerbation rate
- Pre-bronchodilator FEV1
Latest Update
January 2026
Phase 2b showed benefit across all asthma phenotypes including those not responsive to existing biologics.